Saturday 17 October 2026 Export IMA’s income statement to Excel — free account

ImageneBio, Inc.

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.04 0.01 +0.25%

Follow IMA

Alert me

Market cap: $45.7M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 3/9
Altman Z: −1.12
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Total sells 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	1	—	—	—

Insider Ownership 55.08%

Capital & Financial Ratios $m

Market Cap 45.74

Revenue 6.14

Net Income (52.48)

Free Cash Flow (52.59)

Net Debt (136.15)

Current Ratio 21.47

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.33)

P/S ratio 10.63

P/B ratio 0.46

Past 5Y EPS Growth —

This Y EPS Growth 66.60%

Next Y EPS Growth (8.00%)

Next Y revenue growth (66.66%)

Next 5Y EPS Growth 27.01%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 74.66%

10-year low 10-year high

P/B against its own 10 years 34.93%

10-year low 10-year high

EV/Sales against its own 10 years 34.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	175	12	135	136
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	179	12	140	141

	2023	2024	2025	Q'26
Payables	2	5	1	1
ST’ Debt	—	8	—	—
Other	—	—	—	—
	14	17	11	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	(38.64%)	(62.86%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(3.24%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	1	—	—	—	1
’24	—	—	4	—	4
’23	5	2	1	1	9
’22	3	0	6	5	16
’21	3	4	4	20	31
’20	3	3	3	0	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(9)	—	—	—
’25	(7)	(12)	(21)	(7)	(48)
’24	(18)	(13)	13	(3)	(21)
’23	(20)	(18)	(20)	(22)	(80)
’22	(20)	(19)	(17)	(18)	(74)
’21	(13)	(16)	(18)	(13)	(60)
’20	(10)	(8)	(8)	(13)	(38)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(9)	—	—	—
’25	(7)	(12)	(21)	(7)	(48)
’24	(18)	(12)	14	(3)	(20)
’23	(20)	(18)	(20)	(22)	(80)
’22	(20)	(19)	(18)	(18)	(76)
’21	(14)	(16)	(18)	(14)	(62)
’20	(10)	(8)	(8)	(13)	(39)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.95)	(0.63)	—	—	—
’25	(2.16)	(0.72)	(2.91)	(0.73)	(9.64)
’24	(3.96)	(3.36)	(2.52)	(20.92)	(12.24)
’23	(4.68)	(5.28)	(4.80)	(4.92)	(19.57)
’22	(5.64)	(6.84)	(5.76)	(4.68)	(22.81)
’21	(30.25)	(4.20)	(4.80)	0.84	(14.65)
’20	(31.39)	(22.75)	(28.09)	(109.92)	(192.15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	115.56	23.28	12.24	14.64	5.70	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	451.32	172.14	91.68	24.84	20.40
People
People	Employees	—	—	—	—	33	67	80	43	10	15
	Revenue/emp, $m	—	—	0.00	0.00	0.28	0.46	0.20	0.21	0.35	0.05
Income, $m
Income, $m	Revenue	—	—	1	14	9	31	16	9	4	1
	Gross margin, %	—	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(41)	(17)	(44)	(34)	(69)	(68)	(37)	(46)
	EBT margin, %	—	—	(4,127.78)	(122.28)	(481.36)	(110.10)	(440.29)	(745.94)	(1,044.43)	(5,712.38)
	Net income	—	0	(41)	(17)	(44)	(34)	(69)	(68)	(37)	(45)
	Depreciation	—	—	0	0	0	1	1	(1)	2	1
Per share, $
Per share, $	Revenue	—	—	0.03	0.38	39.92	13.29	5.18	2.63	2.93	0.16
	Earnings	—	—	(1.14)	(0.47)	(192.15)	(14.65)	(22.81)	(19.57)	(12.24)	(9.64)
	Cash flow	—	—	(0.32)	1.34	(164.25)	(25.85)	(24.58)	(22.94)	(17.86)	(9.82)
	Capex	—	—	0.00	0.00	(3.33)	(0.75)	(0.47)	(0.12)	0.81	0.00
	Free cash flow	—	—	(0.32)	1.34	(167.57)	(26.60)	(25.06)	(23.06)	(17.04)	(9.82)
	Book value	—	—	(1.28)	(1.71)	(438.77)	89.18	48.75	48.83	(134.48)	27.33
	Shares, m	—	—	36	36	0	2	3	3	1	5
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	9.62	9.62	9.62	11.32	6.07	9.06	3.20	5.47
	P/B	—	—	0.00	0.00	0.00	1.69	0.64	0.49	0.00	0.25
	EV/Sales	—	—	0.54	0.54	0.54	6.43	1.19	(1.10)	13.30	(2.50)
	EV/FCF	—	—	(0.13)	(0.13)	(0.13)	(3.21)	(0.25)	0.13	(4.80)	0.33
Cash, $m
Cash, $m	Operating cash flow	—	—	(12)	48	(38)	(60)	(74)	(80)	(21)	(48)
	Capex	—	—	0	0	(1)	(2)	(1)	0	1	—
	Free cash flow	—	—	(12)	48	(39)	(62)	(76)	(80)	(20)	(48)
Balance, $m
Balance, $m	Working capital	—	—	16	61	138	209	139	164	(5)	129
	Total debt	—	—	63	79	0	2	2	—	8	—
	Net debt	—	—	44	(3)	(162)	(230)	(155)	(175)	(5)	(135)
	Shareholders’ equity	—	—	(46)	(61)	(101)	208	147	170	(161)	133
Returns, %
Returns, %	ROA	—	—	(395.29)	(31.54)	(34.80)	(16.39)	(32.73)	(37.42)	(46.52)	(62.04)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	76.17	31.34	54.47	(63.87)	(38.76)	(43.04)	989.95	225.87

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$47.6M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)	Compare
TVGN Tevogen Inc.	$46.1M	— (loss-making)	—	—	n/m	+5.78% (above 0%: growing)	—	0.00%	Compare
INMB INmune Bio, Inc.	$45.8M	— (loss-making)	— (loss-making)	+8.70% (above 0%: growing)	n/m	+55.39% (above 0%: growing)	100.00%	0.00%	Compare
IMA ImageneBio, Inc.	$45.7M	— (loss-making)	— (loss-making)	−60.08% (below 0%: shrinking)	n/m	+23.76% (above 0%: growing)	100.00%	0.00%
SER Serina Therapeutics, Inc.	$45.5M	— (loss-making)	— (loss-making)	+2,500.00% (above 0%: growing)	n/m	−76.82% (below 0%: shrinking)	100.00%	0.00%	Compare
ANVS Annovis Bio, Inc.	$44.8M	— (loss-making)	—	—	n/m	−329.18% (below 0%: shrinking)	—	0.00%	Compare
ALDX Aldeyra Therapeutics, Inc.	$44.5M	— (loss-making)	—	—	n/m	+46.09% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$46.0M	—	—	+166.67%	—	+8.85%	80.00%	0.00%

All 614 Biotechnology stocks →

ImageneBio, Inc. (IMA) key facts

Concern: ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024.
ImageneBio, Inc. (IMA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IMA traded at $4.04, a market capitalization of $45.7 million.
Return on equity was 225.9% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −1.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.